FDA Grants Alvotech Expanded U.S. Manufacturing Rights for SIMLANDI®

On 5 October 2026, the U.S. Food and Drug Administration (FDA) approved a supplement to Alvotech S.A.’s Biologics License Application for AVT02, the company’s biosimilar to Humira® (commercially known as SIMLANDI®). The approval enables the drug substance for AVT02 to be manufactured in either of Alvotech’s two production suites—DSM1 or the newly authorized DSM2—at the Reykjavik facility. This development follows the July 2026 FDA inspection, during which a Voluntary Action Indicated (VAI) classification was assigned to the site. Alvotech’s subsequent corrective actions have satisfied regulatory scrutiny, culminating in this milestone.

Operational Impact

The DSM2 suite supports the entire drug‑substance manufacturing chain, from cell culture to purification. By adding DSM2 to the U.S. supply portfolio, Alvotech effectively doubles the production capacity for AVT02. This expansion offers:

  • Greater Flexibility: Dual manufacturing locations allow the company to adjust production in response to market demand and supply‑chain contingencies.
  • Enhanced Supply Assurance: With two independent production lines, the risk of shortages in the U.S. market is mitigated.
  • Scalability for Future Products: DSM2 is already approved for European markets to manufacture AVT02, AVT03, and AVT05, positioning Alvotech to accelerate commercial roll‑outs for its biosimilar pipeline.

Regulatory Significance

The FDA’s decision is not merely an operational win; it represents a critical regulatory validation of Alvotech’s quality systems and manufacturing operations. The company’s CEO, Lisa Graver, emphasized that the approval confirms the “significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.” The supplemental approval also signals confidence that the corrective actions taken post‑inspection have adequately addressed all identified concerns.

Market Context

Alvotech, listed on the Nasdaq under the ticker ALVO, operates in the global biotechnology sector with a focus on biosimilar medicines for autoimmune disorders, eye diseases, osteoporosis, and cancer. The company’s market capitalization stands at approximately US 1.95 billion, and its share price on 1 October 2026 closed at US 5.45. While the firm’s price‑earnings ratio is negative—reflecting ongoing investment in development and production—the FDA approval is expected to enhance investor perception of commercial viability in the U.S. market.

Outlook

With the Reykjavik facility now capable of supporting U.S. supply from both DSM1 and DSM2, Alvotech is better positioned to meet the growing demand for cost‑effective alternatives to Humira®. The expanded manufacturing capacity should translate into stronger commercial performance, potentially improving the company’s earnings profile and reinforcing its standing among peers in the biosimilars landscape.